Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

E. Geyer, Charles; Forster, John; Lindquist, Deborah; Chan, Stephen; Gilles Romieu, C.; Pieńkowski, Tadeusz; Jagiełło-Gruszfeld, Agnieszka; Crown, John; Chan, Arlene; Kaufman, Bella; Skarlos, Dimosthenis; Campone, Mario; Davidson, Neville; S. Berger, Mark; Oliva, Cristina; D. Rubin, Stephen; Stein, Steven; Cameron, David

doi:10.1056/nejmoa064320

Public

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Published in New England Journal of Medicine • Dec 27, 2006

Authors:

Charles E. Geyer

John Forster

Deborah Lindquist

Abstract

BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed af...

Subject

Lapatinib

Capecitabine

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!